Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® in previously treated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Brixton Metals Announces Closing of Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
